CLI-10067AA1-02: A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis (clinicaltrialsregister.eu) - Apr 30, 2026 - P1/2 | N=48 | Not yet recruiting | Sponsor: Chiesi Farmaceutici S.p.A.
New P1/2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
|